REGN4461 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
265脂肪萎縮症3

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05088460
(ClinicalTrials.gov)
February 28, 202212/10/2021A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial LipodystrophyFamilial Partial Lipodystrophy;Metabolic AbnormalitiesDrug: REGN4461;Drug: Matching PlaceboRegeneron PharmaceuticalsNULLRecruiting18 YearsN/AAll40Phase 2United States;France;Spain;Turkey
2NCT04710056
(ClinicalTrials.gov)
June 202113/1/2021Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy or 3) Monogenic Obesity Due to LEP or LEPR Loss of FunctionGeneralized Lipodystrophy;Partial Lipodystrophy;Monogenic Obesity Due to LEP or LEPR Loss of FunctionDrug: REGN4461Regeneron PharmaceuticalsNULLAvailableNULL
3NCT04159415
(ClinicalTrials.gov)
January 7, 20207/11/2019Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyA Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyGeneralized LipodystrophyDrug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461Regeneron PharmaceuticalsNULLActive, not recruiting12 YearsN/AAll16Phase 2United States;Peru;Russian Federation;Turkey